[Stimulation, stimulus conduction and myocardial excitability of the human heart under oxyfedrin therapy of bradycardic dysrhythmias (author's transl)].
D000200:Action Potentials / Q000187:drug effects; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001919:Bradycardia / Q000188:drug therapy / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D004562:Electrocardiography; D006327:Heart Block / Q000503:physiopathology; D006329:Heart Conduction System / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011427:Propiophenones / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D013268:Stimulation, Chemical
D000318:Adrenergic beta-Agonists; D000889:Anti-Arrhythmia Agents; D011412:Propanolamines; D011427:Propiophenones
Erregungsbildung, Erregungsleitung und myokardiale Erregbarkeit des menschlichen Herzens unter Oxygedrinbehandlung bei bradykarden Rhythmusstörungen